Search for content, post, videos

Sobi lays off 90 employees

Swedish Orphan Biovitrum has announced that it intends to discontinue discovery/early research and partner R&D programmes outside its core focus areas.

The new focus of the R&D organisation is expected to lead to annual savings of SEK 200–300 M on a full-year basis in 2020, which will increase the company’s financial flexibility to reallocate future investments into late-stage development projects, it states. In 2019 restructuring costs of around SEK 100–200 M relating to the reorganisation and redundancies corresponding to approximately 90 positions will be charged.

Guidance for the full year 2019, excluding restructuring costs, remains unchanged.

 

Read more:

Sobi acquires emapalumab and related assets from Novimmune